phospholipid scramblase family member 5Genealiases: []
Q-omics provides the consensus-scored PLSCR5 profile across patient tissues and cancer cell-line models. PLSCR5 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PLSCR5 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, PLSCR5 RNA expression shows 8,207 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where PLSCR5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLSCR5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLSCR5 survival associations across molecular data types. PLSCR5 RNA expression shows survival associations in the most cancer types (8), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLSCR5 RNA expression–survival associations across cancer types. High PLSCR5 expression shows unfavorable associations in KIRC, THCA, SKCM, CESC and ACC, but favorable associations in PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PLSCR5 RNA expression.
This table summarizes PLSCR5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PLSCR5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLSCR5 shows lower tumor expression in COAD, READ, STAD and BRCA and higher tumor expression in KIRC and LUSC. The COAD box plot shows higher PLSCR5 RNA expression in normal versus tumor tissue (log2 FC = −0.070, t-test p = .001).
This table shows molecular features associated with PLSCR5 in patient tissues and cancer cell lines. In patient samples, PLSCR5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PLSCR5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
